Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Repetition of Prediabetes Enhances the Risk of Developing Diabetes.

Numata Y, Ohya T, Nitta Y, Yoshinaka Y, Shogakiuchi A, Toyota A.

J Diabetes Res. 2019 Mar 12;2019:4916546. doi: 10.1155/2019/4916546. eCollection 2019.

2.

Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.

Shibuya K, Kawamine K, Ozaki C, Ohgiya T, Edano T, Yoshinaka Y, Tsunenari Y.

J Med Chem. 2018 Dec 13;61(23):10635-10650. doi: 10.1021/acs.jmedchem.8b01256. Epub 2018 Nov 29.

PMID:
30433781
3.

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors.

Shibuya K, Kawamine K, Miura T, Ozaki C, Edano T, Mizuno K, Yoshinaka Y, Tsunenari Y.

Bioorg Med Chem. 2018 Aug 7;26(14):4001-4013. doi: 10.1016/j.bmc.2018.06.024. Epub 2018 Jun 19.

PMID:
29945757
4.

Comprehensive geriatric intervention program with and without weekly class-style exercise: research protocol of a cluster randomized controlled trial in Kyoto-Kameoka Study.

Watanabe Y, Yamada Y, Yokoyama K, Yoshida T, Yoshinaka Y, Yoshimoto M, Tanaka Y, Itoi A, Yamagata E, Ebine N, Ishikawa-Takata K, Kimura M.

Clin Interv Aging. 2018 May 24;13:1019-1033. doi: 10.2147/CIA.S151427. eCollection 2018.

5.

Sociodemographic and physical predictors of non-participation in community based physical checkup among older neighbors: a case-control study from the Kyoto-Kameoka longitudinal study, Japan.

Yamaguchi M, Yoshida T, Yamada Y, Watanabe Y, Nanri H, Yokoyama K, Date H, Miyake M, Itoi A, Yamagata E, Masumoto T, Okayama Y, Yoshinaka Y, Kimura M; Kyoto-Kameoka study group.

BMC Public Health. 2018 May 2;18(1):568. doi: 10.1186/s12889-018-5426-5.

6.

Light rhythmic exercise with dietary milk fat globule membrane improves physical fitness in an elderly Japanese population: a double-blind randomized placebo-controlled trial.

Yoshinaka Y, Soga S, Ota N, Yokoyama K, Yamada Y, Kimura M.

Biosci Biotechnol Biochem. 2018 Apr;82(4):677-682. doi: 10.1080/09168451.2017.1412248. Epub 2018 Jan 3.

PMID:
29297260
7.

Prevalence of Frailty Assessed by Fried and Kihon Checklist Indexes in a Prospective Cohort Study: Design and Demographics of the Kyoto-Kameoka Longitudinal Study.

Yamada Y, Nanri H, Watanabe Y, Yoshida T, Yokoyama K, Itoi A, Date H, Yamaguchi M, Miyake M, Yamagata E, Tamiya H, Nishimura M, Fujibayashi M, Ebine N, Yoshida M, Kikutani T, Yoshimura E, Ishikawa-Takata K, Yamada M, Nakaya T, Yoshinaka Y, Fujiwara Y, Arai H, Kimura M.

J Am Med Dir Assoc. 2017 Aug 1;18(8):733.e7-733.e15. doi: 10.1016/j.jamda.2017.02.022. Epub 2017 May 11.

PMID:
28501417
8.

Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.

Yano W, Inoue N, Ito S, Itou T, Yasumura M, Yoshinaka Y, Hagita S, Goto M, Nakagawa T, Inoue K, Tanabe S, Kaku K.

J Diabetes Investig. 2017 Mar;8(2):155-160. doi: 10.1111/jdi.12593. Epub 2016 Dec 15.

9.

[Fall risk factors and sex differences among community-dwelling elderly individuals in Japan. A Kameoka study].

Masumoto T, Yamada Y, Yamada M, Nakaya T, Miyake M, Watanabe Y, Yoshida T, Yokoyama K, Yamagata E, Date H, Nanri H, Komatsu M, Yoshinaka Y, Fujiwara Y, Okayama Y, Kimura M.

Nihon Koshu Eisei Zasshi. 2015;62(8):390-401. doi: 10.11236/jph.62.8_390. Japanese.

10.

Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.

Hori T, Barnor J, Nguyen Huu T, Morinaga O, Hamano A, Ndzinu J, Frimpong A, Minta-Asare K, Amoa-Bosompem M, Brandful J, Odoom J, Bonney J, Tuffour I, Owusu BA, Ofosuhene M, Atchoglo P, Sakyiamah M, Adegle R, Appiah-Opong R, Ampofo W, Koram K, Nyarko A, Okine L, Edoh D, Appiah A, Uto T, Yoshinaka Y, Uota S, Shoyama Y, Yamaoka S.

Biochem Biophys Res Commun. 2015 Apr 3;459(2):288-293. doi: 10.1016/j.bbrc.2015.02.102. Epub 2015 Feb 26. Erratum in: Biochem Biophys Res Commun. 2015 Jun 12;461(4):702.

PMID:
25727021
11.

[Relationship between homebound status and physical fitness in the community-dwelling elderly population].

Yamagata E, Kimura M, Miyake M, Yamada Y, Masumoto T, Watanabe Y, Yoshida T, Yokoyama K, Yoshinaka Y, Sugihara Y, Komatsu M, Okayama Y, Inoue T.

Nihon Koshu Eisei Zasshi. 2014;61(11):671-8. Japanese. No abstract available.

12.

Direct evidence for pitavastatin induced chromatin structure change in the KLF4 gene in endothelial cells.

Maejima T, Inoue T, Kanki Y, Kohro T, Li G, Ohta Y, Kimura H, Kobayashi M, Taguchi A, Tsutsumi S, Iwanari H, Yamamoto S, Aruga H, Dong S, Stevens JF, Poh HM, Yamamoto K, Kawamura T, Mimura I, Suehiro J, Sugiyama A, Kaneki K, Shibata H, Yoshinaka Y, Doi T, Asanuma A, Tanabe S, Tanaka T, Minami T, Hamakubo T, Sakai J, Nozaki N, Aburatani H, Nangaku M, Ruan X, Tanabe H, Ruan Y, Ihara S, Endo A, Kodama T, Wada Y.

PLoS One. 2014 May 5;9(5):e96005. doi: 10.1371/journal.pone.0096005. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99749.

13.

Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application.

Ichiyama K, Gopala Reddy SB, Zhang LF, Chin WX, Muschin T, Heinig L, Suzuki Y, Nanjundappa H, Yoshinaka Y, Ryo A, Nomura N, Ooi EE, Vasudevan SG, Yoshida T, Yamamoto N.

PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2188. doi: 10.1371/journal.pntd.0002188. Print 2013.

14.

Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus.

Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, Sasazuki T, Miyoshi-Akiyama T.

J Virol. 2012 Nov;86(21):11745-53. doi: 10.1128/JVI.01250-12. Epub 2012 Aug 22.

15.

Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.

Miyoshi-Akiyama T, Ishida I, Fukushi M, Yamaguchi K, Matsuoka Y, Ishihara T, Tsukahara M, Hatakeyama S, Itoh N, Morisawa A, Yoshinaka Y, Yamamoto N, Lianfeng Z, Chuan Q, Kirikae T, Sasazuki T.

J Infect Dis. 2011 Jun 1;203(11):1574-81. doi: 10.1093/infdis/jir084.

PMID:
21592986
16.
17.

A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice.

Yoshinaka Y, Shibata H, Kobayashi H, Kuriyama H, Shibuya K, Tanabe S, Watanabe T, Miyazaki A.

Atherosclerosis. 2010 Nov;213(1):85-91. doi: 10.1016/j.atherosclerosis.2010.08.048. Epub 2010 Aug 19.

PMID:
20843517
18.

Temporary scaphotrapezoidal joint fixation for adolescent Kienböck's disease.

Ando Y, Yasuda M, Kazuki K, Hidaka N, Yoshinaka Y.

J Hand Surg Am. 2009 Jan;34(1):14-9. doi: 10.1016/j.jhsa.2008.09.019.

PMID:
19121725
19.

Pycnogenol, a procyanidin-rich extract from French maritime pine, inhibits intracellular replication of HIV-1 as well as its binding to host cells.

Feng WY, Tanaka R, Inagaki Y, Saitoh Y, Chang MO, Amet T, Yamamoto N, Yamaoka S, Yoshinaka Y.

Jpn J Infect Dis. 2008 Jul;61(4):279-85.

20.

Ion-pair chromatographic separation of glycoprotein derived oligosaccharides as their 8-aminopyrene-1,3,6-trisulfonic acid derivatives.

Yoshinaka Y, Ueda Y, Suzuki S.

J Chromatogr A. 2007 Mar 2;1143(1-2):83-7. Epub 2006 Dec 21.

PMID:
17196972
21.

Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models.

Okada M, Takemoto Y, Okuno Y, Hashimoto S, Fukunaga Y, Tanaka T, Kita Y, Kuwayama S, Muraki Y, Kanamaru N, Takai H, Okada C, Sakaguchi Y, Furukawa I, Yamada K, Izumiya M, Yoshida S, Matsumoto M, Kase T, Peiris JS, DeMello DE, Chen PJ, Yamamoto N, Yoshinaka Y, Nomura T, Ishida I, Morikawa S, Tashiro M, Sakatani M.

Adv Exp Med Biol. 2006;581:561-6.

PMID:
17037598
22.

Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.

Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, Herzenberg LA, Hagiwara M.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33. Epub 2006 Jul 13.

23.

A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels.

Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, Sawanobori K, Watanabe T, Miyazaki A.

Atherosclerosis. 2007 Apr;191(2):290-7. Epub 2006 Jul 3.

PMID:
16820149
24.

Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium Aiton.

Zhong Y, Yoshinaka Y, Takeda T, Shimizu N, Yoshizaki S, Inagaki Y, Matsuda S, Honda G, Fujii N, Yamamoto N.

Antiviral Res. 2005 Jun;66(2-3):119-28. Epub 2005 Mar 27.

PMID:
15911029
25.

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice.

Okada M, Takemoto Y, Okuno Y, Hashimoto S, Yoshida S, Fukunaga Y, Tanaka T, Kita Y, Kuwayama S, Muraki Y, Kanamaru N, Takai H, Okada C, Sakaguchi Y, Furukawa I, Yamada K, Matsumoto M, Kase T, Demello DE, Peiris JS, Chen PJ, Yamamoto N, Yoshinaka Y, Nomura T, Ishida I, Morikawa S, Tashiro M, Sakatani M.

Vaccine. 2005 Mar 18;23(17-18):2269-72.

PMID:
15755609
26.

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.

Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N.

Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25.

PMID:
15144898
27.

Triglyceride-lowering effect of pitavastatin [corrected] in a rat model of postprandial lipemia.

Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y.

Eur J Pharmacol. 2002 May 24;444(1-2):107-13.

PMID:
12191589
28.

Effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia.

Yoshinaka Y, Kobayasi H, Kirihara J, Sato F, Shakutou S, Yamanaka H.

Eur Urol. 2000 Apr;37(4):428-35.

PMID:
10765073
29.

Induction of manganese-superoxide dismutase in MRC-5 cells persistently infected with an alphavirus, sindbis.

Yoshinaka Y, Takahashi Y, Nakamura S, Katoh I, Takio K, Ikawa Y.

Biochem Biophys Res Commun. 1999 Jul 22;261(1):139-43.

PMID:
10405336
30.
31.

Acute infection of Sindbis virus induces phosphorylation and intracellular translocation of small heat shock protein HSP27 and activation of p38 MAP kinase signaling pathway.

Nakatsue T, Katoh I, Nakamura S, Takahashi Y, Ikawa Y, Yoshinaka Y.

Biochem Biophys Res Commun. 1998 Dec 9;253(1):59-64.

PMID:
9875220
32.

[Role of virus specific protease on virion morphogenesis].

Yoshinaka Y, Katoh I.

Tanpakushitsu Kakusan Koso. 1998 May;43(6):734-43. Review. Japanese. No abstract available.

PMID:
9612067
33.

Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus.

Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC 2nd, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE.

J Virol. 1998 Apr;72(4):2962-8.

34.
35.

How the developing septo-preoptic medical basal hypothalamus stimulates the development of placode-derived LHRH neurons.

Daikoku S, Koide I, Yoshinaka Y, Oka T, Natori Y.

Arch Histol Cytol. 1995 Mar;58(1):77-95.

PMID:
7542015
36.

Inhibition and entrapment of aspartic proteinases by alpha 2-macroglobulin.

Athauda SB, Arakawa H, Takahashi T, Nishigai M, Ido E, Kyushiki H, Yoshinaka Y, Ikai A, Tang J, Ukai M, et al.

Adv Exp Med Biol. 1995;362:305-13. No abstract available.

PMID:
8540333
37.

Entrapment and inhibition of human immunodeficiency virus proteinase by alpha 2-macroglobulin and structural changes in the inhibitor.

Athauda SB, Ido E, Arakawa H, Nishigai M, Kyushiki H, Yoshinaka Y, Takahashi T, Ikai A, Tang J, Takahashi K.

J Biochem. 1993 Jun;113(6):742-6.

39.

The role of the Maternal and Child Health Handbook system in reducing perinatal mortality in Japan.

Takayanagi K, Iwasaki S, Yoshinaka Y.

Clin Perform Qual Health Care. 1993 Jan-Mar;1(1):29-33.

PMID:
10135606
40.
41.

[Quality management in healthcare. Evaluation and improvement].

Iwasaki S, Takayanagi K, Yoshinaka Y, Fuse R.

Nihon Ika Daigaku Zasshi. 1992 Aug;59(4):289-93. Review. Japanese.

PMID:
1400903
42.

Background of hospital evaluation in Japan.

Kawakita H, Yoshinaka Y.

Jpn Hosp. 1992 Jul;11:43-7. No abstract available.

PMID:
10120547
45.

Retrovirus protease characterized as a dimeric aspartic proteinase.

Katoh I, Ikawa Y, Yoshinaka Y.

J Virol. 1989 May;63(5):2226-32.

47.

[Genes participating in the maturation of AIDS viruses; retrovirus protease].

Yoshinaka Y, Katoh I.

Nihon Rinsho. 1989 Jan;47(1):197-206. Japanese. No abstract available.

PMID:
2657131
48.

[Retroviral protease].

Yoshinaka Y, Katoh I.

Seikagaku. 1988 Sep;60(9):1053-9. Japanese. No abstract available.

PMID:
3073172
49.

Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor.

Katoh I, Yasunaga T, Ikawa Y, Yoshinaka Y.

Nature. 1987 Oct 15-21;329(6140):654-6.

PMID:
2821409
50.

The bovine leukemia virus X region encodes a trans-activator of its long terminal repeat.

Katoh I, Yoshinaka Y, Sagata N, Ikawa Y.

Jpn J Cancer Res. 1987 Feb;78(2):93-8.

PMID:
3030987

Supplemental Content

Loading ...
Support Center